Kaspars Kupics

Dr. Kaspars Kupics

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in European Heart Journal
Verified
Journal Article
Closed access
IGIsabelle C Van Gelder
Isabelle C Van Gelder
MRMichiel Rienstra
Michiel Rienstra
KBKarina V Bunting
Karina V Bunting
RARuben Casado Arroyo
Ruben Casado Arroyo
VCValeria Caso
Valeria Caso
HKHusniddin Kuchkarov
Husniddin Kuchkarov

1 August 2017 in EP Europace
Verified
Journal Article
Closed access
PDF file
Yves De GreefYves De Greef
Yves De Greef
ESEdwin Ströker
Edwin Ströker
BSBruno Schwagten
Bruno Schwagten
Kaspars KupicsKaspars Kupics
Kaspars Kupics
JCJeroen De Cocker
Jeroen De Cocker
IBIan Buysschaert
Ian Buysschaert
To define predictors of complications of pulmonary vein isolation (PVI) and compare safety between different ablation techniques. One thousand patients with atrial fibrillation (AF) (age 60 ± 10, 72% males, CHA2DS2-VASc score 1 ± 1) underwent PVI using various techniques: conventional PVI (CPVI) using mapping with irrigated point-per-point RF ablation (n = 576), multi-electrode RF ablation with the pulmonary vein ablation catheter (PVAC) (n = 272) or high density mesh ablator (HDMA) (n = 59) and cryoballoon (CB) ablation (n = 93). A complication was defined as any procedure-related adverse event resulting in permanent injury or death, requiring intervention or treatment, or prolonging/requiring hospitalization for >48 h. A total of 105 (10.5%) complications occurred in 101 (10.1%) patients. No periprocedural death occurred. Most frequent complications were vascular complications (4%) and pericarditis (3.1%). Seven patients experienced permanent deficit due to PV stenosis (n = 3, 1 CPVI, 2 PVAC) (n = 3) and phrenic nerve palsy (PNP) (n = 4, 3 CPVI, 1 PVAC). Independent predictors of complications were female sex [odds ratio (OR) = 1.73; 95% confidence interval (CI) 1.08–2.79; P = 0.023], CHA2DS2-VASc score (OR = 1.24; 95% CI 1.01–1.52; P = 0.039), and ablation technique (P = 0.006) in multivariable-adjusted analysis. Among the different techniques, CB (P = 0.047) and PVAC ablation (P = 0.003) had lowest overall complication rates. Complication profile (type/severity) differed between techniques (association between CB and PNP, CPVI and pericardial injury, PVAC and transient ischaemic attack/PV stenosis). Overall complication rate of PVI with various techniques is 10.5%. Permanent deficit occurred only after PVAC and CPVI in 0.7% of patients. Female sex and a higher CHA2DS2-VASc score increase, while PVAC and CB-PVI decrease, overall risk. Differences in overall safety and individual complication profile make selection of the ablation technique in relation to clinical risk profile possible.

11 July 2018 in EP Europace
Verified
Journal Article
Closed access
PDF file
ESErwin Ströker
Erwin Ströker
CACarlo de Asmundis
Carlo de Asmundis
Kaspars KupicsKaspars Kupics
Kaspars Kupics
KTKen Takarada
Ken Takarada
Giacomo MugnaiGiacomo Mugnai
Giacomo Mugnai
GCGian Battista Chierchia
Gian Battista Chierchia
Vascular complications are the most common complications of atrial fibrillation (AF) ablation. Cryoballoon (CB) ablation for AF needs the insertion of a large 15 Fr sheath in the femoral vein. Our aim was to investigate the impact of vascular ultrasound (US) in guiding access and evaluating post-procedural subclinical complications in a large, multi-centre patient cohort that underwent CB ablation. A total cohort of 1435 consecutive patients were subdivided in 870 US −/−, 265 US −/+, and 300 US +/+ patients depending on US performance for: venipuncture guidance/post-procedural evaluation. Major clinical complications (requiring intervention and/or prolonged stay) were assessed. Irrespective of the clinical status, major US events were systematically determined in the subgroups with US evaluation 1 day post-procedure, if evidence of inadvertent artery puncture/cannulation (communication between artery and collection or artery-vein, regardless of the thrombosis state). Major clinical events were encountered in 1.7% (15/870), 1.1% (3/265), and 0% of patients in US −/−, US −/+, and US +/+ group, respectively (P = 0.02 between US −/− and US +/+ group). In the US −/− group, 5/10 (50%) of pseudo-aneurysms were diagnosed during readmission after a mean of 24 ± 11 days post-procedure. No delayed presentation was seen in the US −/+ group. Major US events during the US protocol post-procedure were seen in 3.8% (10/265) vs. 0.3% (1/300) of patients in US −/+ vs. US +/+ group, respectively, P = 0.004. US-guided venipuncture was associated with a near-to-zero risk of vascular complications in our patients undergoing CB ablation.

2 December 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
PNPetr Neuzil
Petr Neuzil
BMBéla Merkely
Béla Merkely
AEAndrejs Erglis
Andrejs Erglis
GMGermanas Marinskis
Germanas Marinskis
JGJoris De Groot
Joris De Groot
HHHarold Hastings
Harold Hastings
Background: Many patients requiring a pacemaker have persistent hypertension with systolic blood pressures above recommended levels. We evaluated a pacemaker‐based Programmable Hypertension Control ( PHC ) therapy that uses a sequence of variably timed shorter and longer atrioventricular intervals. Methods and Results: Patients indicated for dual‐chamber pacing with office systolic blood pressure ( oSBP ) >150 mm Hg despite stable medical therapy were implanted with a Moderato™ pulse generator that delivers PHC therapy. Patients were followed for 1 month (Run‐In period) with conventional pacing; those with persistent oSBP >140 mm Hg were included in the study and had PHC therapy activated. The co‐primary efficacy end points were changes in 24‐hour ambulatory systolic blood pressure and oSBP between baseline and 3 months. Safety was assessed by tracking adverse events. Thirty‐five patients met the initial inclusion criteria and underwent Moderato implantation. At 1 month, oSBP was <140 mm Hg in 7 patients who were excluded. PHC was activated in the remaining 27 patients with baseline office blood pressure 166±11/80±10 mm Hg despite an average of 3.2 antihypertensive medications. During the Run‐In period, oSBP and 24‐hour ambulatory systolic blood pressure decreased by 8±13 and 5±12 mm Hg ( P <0.002), respectively. Compared with pre‐ PHC activation measurements, oSBP decreased by another 16±15 mm Hg and 24‐hour ambulatory systolic blood pressure decreased by an additional 10±13 mm Hg (both P <0.01) at 3 months. No device‐related serious adverse effects were noted. Conclusions: In pacemaker patients with persistent hypertension despite medical therapy, oSBP and 24‐hour ambulatory systolic blood pressure are decreased by PHC therapy. Initial indications are that this therapy is a safe and promising therapy for such patients. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 02282033.

29 April 2019 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
ESErwin Ströker
Erwin Ströker
YGYves De Greef
Yves De Greef
BSBruno Schwagten
Bruno Schwagten
Kaspars KupicsKaspars Kupics
Kaspars Kupics
HCHugo Enrique Coutiño
Hugo Enrique Coutiño
CACarlo de Asmundis
Carlo de Asmundis

1 February 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
ESErwin Ströker
Erwin Ströker
Kaspars KupicsKaspars Kupics
Kaspars Kupics
CACarlo de Asmundis
Carlo de Asmundis
Giacomo MugnaiGiacomo Mugnai
Giacomo Mugnai
VRValentina de Regibus
Valentina de Regibus
GCGian-Battista Chierchia
Gian-Battista Chierchia